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Abstract
We devise an approach for targeted molecular design, a problem of interest in com-
putational drug discovery: given a target protein site, we wish to generate a chemical
with both high binding affinity to the target and satisfactory pharmacological proper-
ties. This problem is made difficult by the enormity and discreteness of the space of
potential therapeutics, as well as the graph-structured nature of biomolecular surface
sites. Using a dataset of protein-ligand complexes, we surmount these issues by
extracting a signature of the target site with a graph convolutional network and by
encoding the discrete chemical into a continuous latent vector space. The latter em-
bedding permits gradient-based optimization in molecular space, which we perform
using learned differentiable models of binding affinity and other pharmacological
properties. We show that our approach is able to efficiently optimize these multiple
objectives and discover new molecules with potentially useful binding properties,
validated via docking methods.
1 Introduction
The goal of computational drug design is to assist in the discovery of molecules with therapeutic
potential. Given the vast and rapidly expanding knowledge from molecular biology, one may know the
cellular machinery (usually a protein) responsible for a given disease, and can thus devise a targeted
therapeutic, designed to affect a particular biomolecule within the target pathway. This paradigm,
known as molecular targeting therapy, has shown promise in therapeutic development (e.g. cancer
[1, 2]). However, discovering and constructing a molecule (or ligand) capable of binding a given
target is non-trivial. The space of small molecules with therapeutic potential is estimated to be on
the order of 1060 [3, 4]. More problematic is the discreteness of chemical structure space, in which
minor perturbations can lead to large changes in biochemical properties (such as affinity), preventing
continuous optimization approaches. Further, strong binding affinity to the target is merely necessary,
not sufficient, for a useful therapeutic: the presence of off-target effects, cost, and pharmacological
ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties also play a role in
the efficacy or viability of a drug [5, 6]. Therapeutic design is therefore a multi-objective optimization
problem of considerable difficulty, causing the pharmaceutical industry to struggle to find viable
ligands able to reach the end of the development pipeline [7, 8].
One promising route to alleviating this problem is the use of computational methods, such as virtual
screening [9], molecular docking [10], and quantitative structure-activity relationship (QSAR) models
[11, 12], all of which attempt to predict or characterize affinity of a small molecule to a target. More
recently, the advent of deep learning has improved various prediction tasks in cheminformatics [13, 14],
such as bioactivity scoring [15, 16], organic synthesis planning [17], and toxicity estimation [18]. Of
particular interest, however, is the de novo design of molecules with desirable properties [19, 20] (also
known as the inverse QSAR problem [21, 22, 23]), which has been approached in a variety of ways,
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Figure 1: Schematic overview of model components. Graph site GP and chemical ligand structure
SC are extracted from an input PLC (PDB: 3BHY), and embedded into a vector space via fG and fJ .
The output vectors P and C are then used to compute a predicted binder fS(P ) = Ĉ(P ), estimated
binding affinity fB(C,P ) = B̂(C,P ) = (pB , B̂DSX), and predicted chemical properties (toxicity
fT (C) = L̂tox(C) and drug-likeness fP (C) = φ̂(C)).
including Bayesian optimization in latent space [24, 25, 26, 27, 28], reinforcement learning [29], deep
generative models [30, 31], and recurrent neural networks (RNNs) [32, 33]. Many of these methods,
however, do not address the problem of targeted design, while those that do suffer from short-comings,
such as relying on specialized biochemical models, requiring bound complexes for affinity estimation,
or not utilizing the structural data contained in other protein-ligand pairs.
In this work, we present a novel method to perform targeted design of small molecule agents via
optimization in the latent space of a generative model. First, using a dataset of protein-ligand
complexes (PLCs), we extract and separate the protein binding sites as graph-valued data and the
ligands as discrete chemical SMILES strings [34]. A graph convolutional approach is used to map
the protein sites to a vector signature P , while the Junction Tree Variational Autoencoder (JTVAE)
[26] is used to map the discrete chemical to a latent vector C. Several differentiable models are then
learned via neural networks: (1) a direct mapper, which attempts to reconstruct C from P alone, (2) a
binding affinity estimator, and (3) intrinsic property regressors, which predict the ease of synthesis,
drug-likeness, and toxicity of C. This pipeline is illustrated in Fig. 1. All these models are utilized in
a gradient-based optimization algorithm over latent chemical space, which is given only an embedded
target protein site P and is tasked with finding a small molecule with both strong binding affinity to
the target as well as desirable pharmacological properties.
Our main contributions are to provide ways to circumvent some of the limitations of current approaches.
First, by working in a latent vector space, we can use continuous optimization techniques to perform
efficient gradient-based search over chemical structures. Second, by utilizing a generic representation
of protein surface sites, we can take advantage of the information held in datasets of bound protein-
ligand pairs, meaning we do not necessarily require large amounts of biochemical data for a target
protein (i.e. we attempt to generalize properties of other complexes to our target). Third, we avoid
docking by learning a differentiable scoring function that takes in a protein surface site and ligand
separately. To our knowledge, this is the first work utilizing these techniques for targeted molecular
design, which we hope will prove useful for future endeavors in this area.
2 Related Work
Given the importance of de novo chemical design to the pharmaceutical development process, a
considerable body of work has been devoted to computational methods for improving it (e.g. [14,
20]). Much recent research on constructing continuous embeddings of chemicals has used Bayesian
optimization to generate molecules with desirable properties [24, 25, 26, 27, 32, 28]. However, these
methods do not perform targeted chemical design, aimed at a particular molecule of interest.
Inspired by the success of stochastic gradient-based optimization in training deep neural networks,
we also take advantage of the continuous nature of the latent chemical space, using ADAM [35] for
optimization, rather than a Bayesian approach. This has the disadvantage of requiring differentiable
models for all of the quantities we wish to optimize; however, deep learning models can be used to
satisfy this requirement.
2
Separately, methods of predicting affinity from structural information have also been recently devel-
oped [16, 15]. Such networks take a PLC as input, and use the structural information from the complex
to score the affinity of the bound pair. The main difference between our method and these approaches
is that our affinity prediction network does not receive structural information on the interaction; i.e.
the protein site and putative binding chemical are received independently, as embedded vectors. This
makes the estimation problem more difficult, since detailed atomic interaction information is not
available to the predictor, but more general, since it can be applied to any protein site-chemical pair.
This allows us to avoid a docking step (i.e. to generate a PLC) during our optimization.
The most similar studies to ours perform targeted molecular generation. For instance, the work
by Takeda et al. [36] assists de novo design by visualization of various properties over chemical
space. Other examples include works using RNNs [29, 33] to generate SMILES strings with desired
properties, in particular affinity to a target; these works, as well as the work by Blachke et al. [37],
train their models on biological activity data for specific protein targets (i.e. using a specific QSAR
model). In other words, these models will work best on target protein molecules that already have
considerable data available, concerning known binders and their affinities. This is in contrast to our
method, which attempts to perform a generic mapping from any given target protein site (i.e. “patch”
of atoms from a protein) to a binding chemical. As such, our approach is to rely on learning a general
representation of affinity, based on structural information, rather than specializing to a specific input.
Thus, our algorithm can be applied to targets for which no biochemical data is known; the predictions
of the model will be based on the patterns learned from other complexes. The price to pay for this
generality is the need for structural information; however, the exponential growth of such data bodes
well for this paradigm [38]. Of course, when such activity data is available for a target, it should be
utilized; such information could easily be integrated into our algorithm, simply by adding another
term to the energy function, based on the activity predicted from the specific QSAR model.
3 Molecular Representations
3.1 Latent Chemical Embedding
Considerable progress has been made using deep generative models to embed discrete chemical
structures into continuous latent vector spaces [24, 25, 27, 39]. Such spaces allow the use of continuous
optimization approaches in the latent space to perform efficient search over chemical structures. In this
work, we use the JTVAE via a pretrained model with latent dimensionality 56 (see [26] for details).
Briefly, this method improves over previous SMILES-based methods by working directly in the space
of graphs, resulting in a higher probability of decoding a valid molecule (i.e. one is less likely to
encounter areas of latent space that do not correspond to valid molecules). It utilizes a two-part
molecular encoding: a junction tree encoding, which contains information on substructures within
the chemical, and a graph encoding, which holds details on the atomic connectivity. We use the
concatenation of these two vectors as our latent representation. RDKit [40] was used for chemical
structure processing. Throughout the paper, we denote L as the latent space of chemicals. The JTVAE
thus induces a map fJ : SC → L. We write SC ∈ SC and C ∈ L to mean a discrete chemical
structure and its latent form, respectively (as in Fig. 1).
3.2 Protein Site Signatures via Graph Convolutions
Inspired by the use of graph convolutional networks (GCNs) in extracting fingerprints from chemical
structure graphs [43] and processing protein interface sites [44], we chose to represent our target site in
a graph-theoretic manner (see Fig. 2, right inset). Each site consists of the nitrogen, oxygen, and carbon
atoms within 4Å of the bound ligand as the graph vertices, with features given by the concatenation of
two one-hot vectors, each of length 24: (1) the atomic identity, including the remoteness indicator, and
(2) the amino acid residue identity to which the atom belongs (including four non-standard residues).
The graph is then treated as fully connected, with edge weights given by: eij = 1/(1 + d2ij), where
dij is the Euclidean distance between nodes (atoms) i and j. Protein structure processing was done
with Biopython [45], DeepChem [46], and MDTraj [47].
Our GCN is based on a combination of the fingerprint extraction approach of Duvenaud et al. [43]
and the approximate convolution method of Kipf and Welling [48]. Consider a single input graph GP
for a protein site, with Na atoms and node feature dimensionality NF . Define the space of extracted
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Figure 2: Protein binding and target site characterization. Left: 2D Poseview [41] diagram of chemical
interactions between ligand and protein residues (PDB: 1WVX), where dashed lines mark hydrogen
bonds and green curves demarcate the protein surface. Middle: 3D depiction in Chimera [42] of
a protein-ligand complex (PDB: 3BHY) with surface filled in (red: chemical ligand, blue: protein,
turqoise: binding site). Right: graph-theoretic representation of binding site (nodes are atoms with
atomic and residue identity as features; edge features are based on inter-atomic distances).
signatures to be a vector space P with dimensionality NP ; note that NP is a hyper-parameter, while
Na varies for each input protein. Denote A ∈ RNa×Na as the weighted adjacency matrix (i.e. with
entries eij), Dii =
∑
j Aij , and V ∈ RNa×NF as the matrix of node feature vectors. Let σp denote a
point-wise non-linearity and gSM denote the row-wise softmax function. Then, for every layer ` in the
GCN, we have two matrices of trainable weights: W (`) ∈ RNF×NF , which controls the convolutional
parameters, and W˜ (`) ∈ RNF×NP , which determines the signature extraction. Thus, given inputs V ,
D, and A, we can compute
H(`+1) = σp(D
−1/2AD−1/2H(`)W (`)) (1)
where V = H(0). The final vector P ∈ P is then given by
P =
L∑
`=1
Na∑
k=1
gSM(H
(`)W˜ (`))k (2)
where L is the total number of layers and gSM(M)k refers to the kth row of the output matrix. Here,
we used L = 2, σp = ReLU, and NP = 100. We can thus denote our GCN as a map performing
fG(GP ) = P , as in Fig. 1.
4 Binding Affinity Regression and Direct Mapping
4.1 Affinity Data
The core mechanism of our targeting algorithm relies on a differentiable predictor of binding affinity.
We therefore required a dataset of protein-ligand complexes from which to learn (see Fig. 2 for
visualization of a PLC and binding site). We chose to use the scPDB [49, 50, 51], a database of
protein-ligand complexes from the PDB [52] amenable to cheminformatics studies. Such complexes
are sufficient to estimate a probability of binding, by classifying whether or not a given protein site and
chemical interact. We also examined the presence of affinity data with structural counterparts in the
BMOAD database [53]. This data is useful for evaluating the quality of binding, e.g. differentiating
between the level of affinity for two chemicals binding the same protein.
However, due to the heterogeneity and reduced dataset coverage of the empirical binding affinity
data, we chose to instead use a computational scoring function, which is an in silico method of
estimating binding quality, used for tasks like molecular docking [54]. Scoring functions are not
necessarily well-correlated to experimentally determined affinities [55, 56], though ideally this is a
preferable property. We therefore chose to use DrugScoreX (DSX) [57], as prior studies had found
decent correlation to empirical affinities [58], a scoring function based on the older DrugScore and
DrugScoreCSD functions [59, 60]. DSX is a “knowledge-based potential”, using statistical analysis
of atomic interactions to construct a distance-dependent potential able to assess binding affinity [61].
We ran DSX on all the PLCs in the scPDB to obtain an affinity score for each bound complex. To
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Figure 3: Left: correlation plot between true and predicted DSX on positive data examples (in hun-
dreds); line of best fit (red) has slope 0.82. Middle: normalized frequency plots of the predicted DSX
(in hundreds) on scrambled examples (blue), positive examples (red), and the true DSX distribution
on positive examples (green). Right: normalized frequency plots of the binding probabilities on the
positive (red) and negative (blue) examples.
verify correlation to empirical binding data, we compared the DSX results to the experimental results
in BMOAD, finding significant positive correlations between DSX score and the various experimental
affinities (see Supplementary Material). Our final dataset was separated into a training/validation set
of size 16090, and a held-out test set of size 1000.
4.2 Models
Denote the set of PLCs as a set of tuples (C,P ), representing a latent chemical and embedded protein
site produced by fJ and fG respectively, where each tuple has an associated binding affinityBDSX ∈ R.
We learned two models from this data: (1) fB : L × P → R2 and (2) fS : P → L. The first model
is our affinity model fB(C,P ) = B̂(C,P ) = (pB , B̂DSX), where pB is the probability of binding
and B̂DSX is the predicted DSX (i.e. estimated quality of binding). The second model can be called
a “direct mapper”: given the input protein site P , it attempts to directly construct a binding ligand
structure C. Given the size of chemical space and the potential multiplicity of binders per target site,
we do not expect fS to exactly reproduce the partner ligand (else it may be overfitting); rather, we
simply hope that it maps P to an area in latent space that is favourable to binding P . The direct
mapper can therefore be used to initialize our gradient descent optimization algorithm.
The affinity model was implemented as a neural network with input batch normalization and two
hidden layers (sizes 100 and 50), and regularized with dropout (p = 0.25) and L2 weight decay. The
output pB was also run through a sigmoid function and utilized binary cross-entropy loss, while B̂DSX
used mean-squared error (MSE) loss. The direct mapper had the same architecture, but with layer sizes
150 and 75, dropout probability p = 0.4, and MSE loss. All networks in this paper were implemented
in PyTorch, used ReLU, and were trained with ADAM [35].
We jointly trained the models fG (the GCN that outputs P ), fB , and fS (see Fig. 1). Note that the
losses of both fB and fS affect fG (i.e. both shape the embedding space defined by the protein site
vector signature extractor). To train the predictor, we used the known PLCs as positive examples;
however, for negative examples we “scrambled” the tuples (i.e. matched a random C to a P with
which it did not interact). Negative examples were given a DSX of zero (note that more negative DSX
means better binding). Every minibatch was half positive and half negative examples.
We show the results of the affinity model on the held-out test set in Fig. 3. The results on scrambled data
are computed via 100 random scrambled samples per positive example (thus there are 100 times more
negative examples). The Pearson and Spearman correlation (PC/SC) between the true and predicted
DSX are 0.9 and 0.85 respectively (with significance p < 0.01), showing good agreement between
the true DSX and the output of the regressor on positive examples. The DSX predictor does have
more difficulty differentiating scrambled from unscrambled data, judging from the overlap between
the blue and red distributions (Fig. 3, middle inset); however, the positive distribution is clearly much
closer to the true distribution, and there is a clear spike near zero for the scrambled DSX values. The
mean values with standard error (SE) are −140.7± 2.1, −94.9± 2.0, and −46.1± 0.14 for the true
data, positive predictions, and scrambled predictions, respectively. For the binding probabilities, the
average probability (with SE) for a positive pair was 0.651± 0.006, while the average probability for
a scrambled pair was 0.38± 0.001 (AUROC: 0.79).
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Figure 4: Chemical property prediction and direct mapper results. Upper Row: relative error distribu-
tion on logP, QED, and SAS, respectively. Lower Row: error in toxicity prediction (left) and log ratio
of expected squared distance error for the direct mapper (middle on the training set and right on the
test set; the dashed red lines indicate the means of the RE values, at 0.467± 0.01 and 0.434± 0.004
with SE, for the training and testing data, respectively).
Evaluating the direct mapper fS is more difficult. As noted above, we cannot expect it to output
the exact answer; furthermore, simply reporting the Euclidean distance in latent space is a highly
unintuitive measure of error. We therefore define a metric RE(P,C), which is designed to measure
how much closer the output molecule Ĉ = fS(P ) is to the true binder agent C, compared to a
randomly chosen chemical C˜ from the prior over our latent space. We can thus define an error given
by the log ratio of expected squared distance as
RE(P,C) = log
(
EC˜∼N (0,I)
[
||C − C˜||22
||C − fS(P )||22
])
= log
( ||C||22 + dim(L)
||C − fS(P )||22
)
(3)
which follows from ||C − C˜||22 being non-central Chi-squared distributed. When RE is equal to zero,
then the direct mapper is at a distance no better than what we expect to attain by random chance; when
RE < 0, the direct mapper is doing worse than randomly sampling from the prior. Thus, we hope to
see a positive RE score, which implies fS maps P to a part of L that is closer to C than random. We
assume that the neighbourhood of a binder is more likely to favour producing other binders of P .
The results of the direct mapper are shown in Fig. 4 (bottom row, middle and right). The vast majority
of the data are greater than zero, indicating that the direct mapper is able to map closer to the true
binder than one would expect by chance. We show the results on both the training and testing set:
means with SE are 0.467 ± 0.01 and 0.434 ± 0.004. Given their similarity, we are confident that
the model is not overfitting. As a side note, it is possible that L could contain the binders of P in
disjoint areas of space, which would be problematic for the direct mapper fS . This could potentially
be mitigated by jointly training fJ as well, but we leave this approach to future work.
5 Chemical Property Prediction
Targeted drug design cannot only take predicted binding strength into account; it must also consider
molecular properties of a candidate therapeutic. Indeed, molecules with good binding capabilities,
but poor pharmacokinetics and toxicity properties, can result in costly failures as drugs [62, 63]. We
therefore consider the predicted toxicity and several drug-likeness properties of the chemical as well.
First, we considered estimating the toxicological properties of a given small molecule. We used
the Tox21 dataset [64], which includes binary data on the activation of five cellular stress response
pathways. Not all chemicals have data for all toxicity measures; hence, we use the average toxicity
of the measures that were present as the output label, denoted Ltox(C). However, the dataset is very
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Algorithm 1 Molecular Optimization
1: procedure LATENTOPT(P , T , η)
2: C0 = fS(P )
3: for t = 1 to T do
4: v ← ∇EP (Ct−1)
5: Ct ← ADAM(Ct−1, η, v)
6: end for
7: return CT
8: end procedure
Figure 5: Latent space molecular optimization algorithm. The input protein target site P is used to
first construct and then iteratively improve a molecule C via gradient descent on an energy E .
imbalanced, since most of the molecules have a zero average toxicity (see Supplementary Material).
We therefore linearly upweighted positive data points via: Wtox(C) = (Wm − 1)Ltox(C) + 1, where
we fixed Wm = 5 based on the frequency of positive values in the dataset. For our estimator, let
fT : L → [0, 1] be the toxicity predictor. Its architecture is the same as that used to compute pB ,
but without batch normalization. Fig. 4 (bottom left) shows the distribution of the error ErrT =
fT (C)− Ltox(C) on a held-out test set of size 250 (mean with SE of |ErrT |: 0.14± 0.009; PC: 0.54).
Note that the prediction errors are skewed to the positive values, due to the weighting function.
We also looked at three chemical properties, known to be associated with drug-likeness: the partition
coefficient logP, which controls the lipophilicity (and thus affects the pharmacokinetic and ADMET
properties of the molecule [6, 65]), the Quantitative Estimation of Drug-Likeness (QED), which
attempts to quantify the aesthetic judgment of medicinal chemists [66], and the synthetic accessibility
score (SAS), which estimates the difficulty in synthesis for a given compound [67]. We use the
ZINC250K dataset, as extracted by [24] from the ZINC dataset [68]. Given a molecule C, denote
the logP, QED, and SAS as the components of a vector φ(C) = (φlogP, φQED, φSAS). We construct a
function fP : L → R3 that estimates φ(C), implemented as a neural network with two hidden layers
(sizes 120 and 60), trained using MSE loss, and regularized with dropout (p = 0.5) and weight decay.
The prediction results are shown as the distribution of relative errors (i.e. |φi(C)−fP (C)i|/mean(φi))
on a held-out test set of size 20000 in Fig. 4 (top row). The mean and SE for logP, SAS, and QED
are 0.26 ± 0.002, 0.1 ± 0.0006, and 0.14 ± 0.001 (PC: 0.8, 0.87, and 0.37). This suggests that the
estimated values of the various chemical drug-likeness properties are within a reasonable range of
their true values.
6 Molecular Optimization
Given the differentiable models above, it is straightforward to define the gradient descent procedure in
the latent space (depicted in Fig. 5). We need only to define the energy we are minimizing:
EP (C) = EB(C,P ) + EP (C) (4)
EB(C,P ) = α1pB(C,P ) + α2gh(B̂DSX(C,P )) (5)
EP (C) = γ1gq(φ̂logP(C)) + γ2φ̂QED(C) + γ3φ̂SAS(C) + γ4fT (C) (6)
for a fixed target input P and variable latent chemical C, where fP = (φ̂logP, φ̂QED, φ̂SAS) and
fB = (pB , B̂DSX). The first term in equation 4 acts as the targeting term, ensuring the resulting
chemical has good predicted binding affinity to the target; the second term encourages the molecule to
have pharmacologically desirable chemical properties. We also view this latter intrinsic energy as a
regularizer, preventing the optimization from exploiting anomalous behaviour of the affinity predictor.
We chose α = (−10, 1/200) and γ = (−0.5,−1, 0.1, 1).
Two terms have additional transformations applied to them. The first is an offset rectifier on the
predicted DSX: gh(x) = max(−250, x), used to limit the term’s influence when it had started to
reach the edge of biophysically plausible values (few real DSX values were below −300). The second
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Figure 6: Energy function component values during optimization. Blue line is average value, over
the 1000 members of the test set; the green shaded area is the standard deviation (over PLCs) per
time point. Time is in units of 104 steps. Top: estimated binding probability, DSX (in hundreds), and
toxicity. Bottom: estimated logP, QED, and SAS.
Figure 7: Visualization of moieties found during optimization of target sites from held-out-test set.
Left: start of algorithm (output of fS). Middle: output of gradient descent after 20000 steps. Right:
known binder chemical. Each row corresponds to a single input P . Two latent space samples are
shown for the start and end chemicals.
is a quadratic function on the logP: gq(x) = −4x(x− 5)/25, which encourages the logP to stay near
the middle of [0, 5]. While sufficiently high logP is required for physiological transport of the drug, a
logP > 5 violates Lipinski’s “rule of five” [69] and a logP > 3 increases probability of toxicity [62];
as such, some literature suggest aiming for a logP within ∼1-3 [65].
We tested our optimization algorithm on the target protein sites from the held-out PLC test set of
size 1000 utilized above (i.e. they were unknown to any of the models). The resulting components of
the energy function over time are shown in Fig. 6. It is clear that the predicted binding probability
and DSX are indicating strong estimated affinity for the majority of input targets by the end of the
optimization. All of the intrinsic properties are also improved: logP stays near 2, while QED steadily
increases, and both toxicity and SAS decrease.
Next, we qualitatively visualize some results. While we cannot say whether the chemicals output by
the latent space optimization are good binders in reality or not, we can check if they have chemical
moieties in common with the known binding ligand (which neither the algorithm nor the affinity
model had access to), which would suggest the model learned a structural pattern in the protein site
and associated latent molecule data that generalized to unseen graphs. See Fig. 7 for examples of this
phenomenon occurring. For instance, in the first row of the figure, the known binder is close to being
a subgraph of the output chemicals, while in the second and third row, the resulting chemical after
optimization is qualitatively more similar to the binding ligand.
Finally, we discuss quantitative evaluation of our optimization algorithm (see Fig. 8). This was done
by docking generated ligands to their target proteins, and then estimating the DSX score of the bound
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Figure 8: Docking validation
results. Left: DSX scores
DT (blue), DR (red), and DC
(green). Right: DSX difference
histograms of ∆ (orange) and ∆S
(purple); lines at medians.
complex; we compare the results to the DSX scores that result from generating random chemicals and
docking one to each protein target. We used Open Babel [70] for preprocessing and rDock [71] for
protein-ligand docking. In detail, for each target protein in the test set Pi, we generate two chemicals:
Ci, the output of our optimization algorithm on Pi, and Ri, a ligand drawn from the latent prior of the
JTVAE. Using rDock, we then dock each of Ri and Ci to Pi separately, obtaining two new bound
complexes, from which we can estimate DSX scores Dr(i) and Dc(i). For docking, since each Pi
has a known binder, the “reference ligand” approach to cavity generation is used, which restricts
the input chemicals to bind to the same site as the known ligand; each docking is run 5 times, and
we take the conformation with minimal DSX. Denote the ordered sets of DSX scores of the true,
random, and latent binders as DT , DR, and DC respectively; we also consider the set of differences
∆ = {Dr(i) − Dc(i) ∀ i}, so that a positive difference indicates that the optimized chemical has
a better DSX score than its random counterpart. Out of 1000 PLCs in the test set, we obtained 961
pairs of docked complexes. In 631 of these (65.7%), the optimized DSX was lower than its random
counterpart; further, while only 246 complexes with random ligands had a DSX less than −100, there
were 477 optimized ligands with DSX score below that. The DSX differences ∆ had a median of 14.5,
mean of 9.3, and standard deviation of 51.5. Altogether, these results suggest the optimized ligands
are enriched with better binders than one would expect to obtain by random sampling.
One issue is that, when the docking or scoring algorithm fails, we are essentially comparing two
random ligands. If we want to look only at the data for which all pipeline components appear to have
produced reasonable results (i.e. to see if it is better than random then), as well as eliminate physically
implausible outliers, we can restrict our attention to the case when the DSX is less than −100. On this
subset, 443 (92.9%) of the optimized docked complexes have better DSX scores than their random
counterparts. The differences on this subset ∆S = {Dr(i)−Dc(i) |Dc(i) < −100} had a median
of 35.4, mean of 36.4, and standard deviation of 26.3. Overall, while these results rely on simulated
dockings, rather than empirical experiment, they still provide independent validation of the utility of
our approach in generating targeted chemical ligands.
7 Discussion
We have proposed an algorithm for targeted therapeutic design: given an input site on a molecule
of interest, we wish to generate an agent with satisfactory predicted binding affinity and chemical
properties. While both protein binding sites and ligands are inherently discrete and highly structured
entities, the use of a graph convolutional signature extraction technique and a deep generative latent
variable encoder over chemical structures allows us to embed them into continuous vector spaces.
By learning differentiable models of target affinity and intrinsic molecular properties, we are able to
utilize gradient-based optimization methods to perform targeted de novo design.
In terms of future work, one could consider other scoring functions (e.g. based on learning [72]), mod-
els (e.g. manifold-theoretic geometric learning techniques [73] or using adversarial generative models),
data modalities (e.g. augmenting with biochemical data or QSAR models), and search regularizers (e.g.
penalizing latent distance from the origin, to help ensure molecular validity). Additional validation,
e.g. via other docking methods or molecular dynamics, would also be useful, particularly given that
docking can sometimes be unreliable [74, 75]. Overall, our results suggest that this approach could be
a promising avenue for future progress in computational drug design.
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Supp. Figure 1. Correlation between the computational scoring function value from DSX and
empirical binding affinity metrics from BMOAD. Left to right: log IC50, logKi, and logKd. Note
that the results for Ka are not shown, since there were only 36 data points. See Supp. Table 1. for
correlation values. Blue line corresponds to the line of best fit.
Pearson Spearman Size
ρp Pp ρs Ps
logKd 0.26 < 10−14 0.26 < 10−14 863
log IC50 0.42 < 10−14 0.45 < 10−14 1649
logKi 0.48 < 10−14 0.49 < 10−14 1250
logKa 0.22 0.19 0.04 0.81 36
Supp. Table 1. Correlations of empirical binding affinity measurements from BMOAD to DSX values.
See Supp. Figure 1. for visualization.
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Supp. Figure 2. Histogram of experimentally determined average toxicity values. X-axis represents
averaged toxicity value, while the Y-axis is the frequency count in thousands. Note the imbalanced
nature of the dataset.
